Oral News and Research

RSS

AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy

UCB today announced that the antiepileptic drug (AED) Vimpat- (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.

12 Mar 2010

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

ACCESS PHARMACEUTICALS, INC. announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies. The studies, which confirm earlier findings, were performed as part of on-going work with commercial collaborators that are evaluating Access' Cobalamin™ Oral Drug Delivery Technology.

12 Mar 2010

Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy

UCB today announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.

12 Mar 2010

$ASBMR Task Force studies link between long-term bisphosphonate usage and rare bone fractures$

ASBMR Task Force studies link between long-term bisphosphonate usage and rare bone fractures

Recent reports suggesting a link between long-term bisphosphonate usage and rare bone fractures have sparked rising concern among patients, health care professionals and the public. The American Society of Bone and Mineral Research (ASBMR) is examining this urgent clinical issue and will present its findings later this year.

12 Mar 2010

WHO welcomes Gates Foundation support in advancing global vaccine efforts

WHO welcomes the Bill & Melinda Gates Foundation pledge of US$ 10 billion over the next ten years to accelerate global vaccine efforts.

12 Mar 2010

FDA provides guidance on Restanza clinical program in treatment of CABP

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that the U.S. Food and Drug Administration has provided guidance on the clinical program required to assess the approvability of Restanza™ (cethromycin), a novel oral once-a-day antibiotic, in the treatment of outpatient community acquired bacterial pneumonia (CABP) as well as biodefense indications including anthrax, plague and tularemia.

11 Mar 2010

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2009.

11 Mar 2010

DenMat's LUMINEERS Smile Design Studio to produce Snap-On Smile

DenMat Holdings, LLC, has recently announced its acquisition of the Snap-On Smile® brand and all intellectual property surrounding it. Snap-On Smile will be produced exclusively by DenMat's LUMINEERS® Smile Design Studio, an ISO 9001 certified laboratory offering a comprehensive range of superior esthetic and restorative services.

11 Mar 2010

Survey: Acute migraine therapy would earn 45% patient share in treatment of migraine

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an acute migraine therapy that is not contraindicated in patients with a history, symptoms or signs of vascular disease and also offers improved efficacy and fast-acting oral delivery would earn a 45 percent patient share in the treatment of migraine, according to surveyed U.S. neurologists.

11 Mar 2010

Data from novel Hedgehog pathway inhibitor program to be presented at upcoming conferences

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that members of its senior leadership and scientific teams will be leading discussions and presenting data from its novel Hedgehog pathway inhibitor program – an emerging area of cancer research – at several upcoming conferences.

11 Mar 2010

Cellectis’ 1485475 European patent: EPO confirms revocation of previously granted claims

Precision BioSciences, Inc., today announced that the Opposition Division of the European Patent Office has issued a written decision confirming its November 18, 2009 revocation of the previously granted claims of Cellectis’ European Patent No. 1 485 475.

11 Mar 2010

New changes made to the Dose Conversion Guidelines on Fentanyl Transdermal Systems

The manufacturers of Fentanyl Transdermal Systems, in collaboration with Health Canada, would like to inform Canadians of important new changes made to the Dose Conversion Guidelines in the Product Monograph. These guidelines are used to help determine what dosage of Fentanyl Transdermal Systems is appropriate for each individual patient.

11 Mar 2010

Evotec completes first-in-human Phase I study of EVT 103 for treatment-resistant depression

Evotec AG today announced two positive aspects that strengthen its integrated product development in treatment-resistant depression in its strategic alliance with Roche.

11 Mar 2010

WHO issues new guidelines for malaria treatment

The World Health Organization (WHO) is releasing new guidelines for the treatment of malaria, and the first ever guidance on procuring safe and efficacious anti-malarial medicines.

11 Mar 2010

Watson Pharmaceuticals resolves Actos patent litigation

Watson Pharmaceuticals, Inc, today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets.

11 Mar 2010

XenaCare Holdings' Cobroxin to be available for purchase in Walgreens

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, will be available for purchase in Walgreens by May 1, 2010. Walgreens is considered one of the nation’s largest pharmacy chains with 7,162 drugstores located throughout the United States.

11 Mar 2010

6 Day Dental and Orthodontics improves access to oral health care

6 Day Dental and Orthodontics now accepts Medicaid and CHIP at all five 6 Day locations – in Allen, Coppell, Frisco/Plano, Flower Mound and Roanoke/Keller.

11 Mar 2010

Cardiologists to highlight capabilities of InfraReDx' LipiScan Coronary Imaging System at ACC.10 and i2 Summit

InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company's LipiScan™ Coronary Imaging System will be highlighted in multiple sessions during the 59th Annual Scientific Session of the American College of Cardiology.

11 Mar 2010

Polio immunization campaign begins across West and Central Africa

More than 85 million children under five years old will be immunized against polio in 19 countries across West and Central Africa in a massive example of cross-border cooperation aimed at stopping a year-long polio epidemic.

10 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Oral News and Research

AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy

ASBMR Task Force studies link between long-term bisphosphonate usage and rare bone fractures

WHO welcomes Gates Foundation support in advancing global vaccine efforts

FDA provides guidance on Restanza clinical program in treatment of CABP

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

DenMat's LUMINEERS Smile Design Studio to produce Snap-On Smile

Survey: Acute migraine therapy would earn 45% patient share in treatment of migraine

Data from novel Hedgehog pathway inhibitor program to be presented at upcoming conferences

Cellectis’ 1485475 European patent: EPO confirms revocation of previously granted claims

New changes made to the Dose Conversion Guidelines on Fentanyl Transdermal Systems

Evotec completes first-in-human Phase I study of EVT 103 for treatment-resistant depression

WHO issues new guidelines for malaria treatment

Watson Pharmaceuticals resolves Actos patent litigation

XenaCare Holdings' Cobroxin to be available for purchase in Walgreens

6 Day Dental and Orthodontics improves access to oral health care

Cardiologists to highlight capabilities of InfraReDx' LipiScan Coronary Imaging System at ACC.10 and i2 Summit

Polio immunization campaign begins across West and Central Africa

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News